Left ventricular remodeling following septal myectomy in hypertrophic obstructive cardiomyopathy

Tsuyoshi Yamabe, MD,a,b Jonathan Ginnns, MD,c Vijay Vedula, PhD,d Jay S. Leb, MD,e Yuichi J. Shimada, MD, MPH,f Shepard D. Weiner, MD,f and Hiroo Takayama, MD, PhDa

ABSTRACT

Objectives: The purpose of this study is to determine whether or not left ventricular remodeling can be induced after septal myectomy in patients with obstructive hypertrophic cardiomyopathy, and if so, how it occurs, using gated cardiac computed tomography.

Methods: Fifty patients with hypertrophic obstructive cardiomyopathy who underwent septal myectomy along the septal band between March 2016 and July 2020 were retrospectively reviewed. Recent consecutive 19 patients underwent postoperative cardiac computed tomography. In these patients, volumes of the septal band and thickness of 17 left ventricular myocardial segments were measured to determine the changes after surgery.

Results: The resection volume predicted by preoperative computed tomography and the actual resection volume were 6.7 ± 3.3 mL and 6.4 ± 2.7 mL. In-hospital mortality was 0%. Moderate or greater mitral valve regurgitation and systolic anterior motion decreased from 56% to 6% and 86% to 6%, respectively. Median preoperative ventricular septal thickness and left ventricular outflow tract pressure gradient at rest decreased from 20.0 mm (interquartile range, 17.0-24.0 mm) and 74.0 mm Hg (interquartile range, 42.5-92.5 mm Hg) to 14.0 mm (interquartile range, 11.5-16.0 mm) and 15.5 mm Hg (interquartile range, 12.1-21.5 mm Hg), respectively. Postoperative computed tomography confirmed a reduction in septal band volume of 5.7 ± 2.8 mL. Total left ventricular myocardial volume was reduced by 12.9 ± 8.8 mL, which exceeded the volume reduction of the resected septal band. All segments except the basal inferior and basal inferolateral regions showed a significant decrease in wall thickness by a median of 6.4%.

Conclusions: Properly performed septal myectomy may induce remodeling of the entire left ventricle, not just the resected area. (JTCVS Open 2022;11:105-15)

Up to 70% of patients with hypertrophic cardiomyopathy (HCM) have the left ventricular outflow tract (LVOT) obstruction.1 The left ventricle (LV) develops diffuse hypertrophy due to a combination of 2 factors: a disease process in which genetic factors affect cardiomyocytes, and secondary hypertrophy caused by increased afterload.2 Septal reduction therapy with surgical septal myectomy (SM) and alcohol septal ablation is utilized to relieve symptoms refractory to maximal medical therapy.3-5 These procedures reduce the LVOT pressure gradient and alleviate the progressive heart failure in patients with obstructive HCM.6-8

CENTRAL MESSAGE

Properly performed septal myectomy may induce remodeling of the entire left ventricle beyond the actual resection area.

PERSPECTIVE

Septal myectomy has the potential to reverse the progression of left ventricular hypertrophy.

From the 1Division of Cardiothoracic and Vascular Surgery, and Departments of 2Radiology and 3Medicine Cardiology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY; 4Department of Cardiovascular Surgery, Shonan-Kamakura General Hospital, Kamakura, Kanagawa, Japan; 5Department of Cardiology, Heart Hospital of Austin, Tex; and 6Department of Mechanical Engineering, Columbia University, New York, NY.

Read at the 101st Annual Meeting of The American Association for Thoracic Surgery: A Virtual Learning Experience, April 30-May 2, 2021.

Received for publication April 29, 2021; revisions received April 1, 2022; accepted for publication May 26, 2022; available ahead of print Aug 8, 2022.

Address for reprints: Hiroo Takayama, MD, PhD, Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital, Columbia University Medical Center, 177 Fort Washington Ave, New York, NY 10032 (E-mail: ht2225@columbia.edu).

2666-2736

Copyright © 2022 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

https://doi.org/10.1016/j.xjon.2022.05.018
introduced 2 surgical concepts: septal band and virtual myectomy. These features associated with relevant surgical anatomies. The volumes of total LV myocardium and septal band were calculated. In addition, the thickness in 17 segments of LV myocardium, including the ventricular septum were measured.

Patient Management

ECG. All patients underwent a comprehensive preoperative transthoracic echocardiogram (TTE), with Valsalva maneuver. LVOT peak velocity was measured by continuous wave Doppler echocardiography; if the LVOT peak pressure gradient exceeded 100 mm Hg, no provocative maneuver was performed. The degree of mitral regurgitation was assessed on a scale of 0 to 4 (0 = none, 1 = trivial, 2 = mild, 3 = moderate, and 4 = severe). All patients underwent predischARGE and follow-up TTE. The follow-up TTE was performed in 6 patients within 1 month, in 11 patients between 1 and 3 months, in 7 patients between 3 and 6 months, in 10 patients between 6 months and 1 year, and in 15 patients after 1 year postoperatively. Transesophageal echocardiography (TEE) was performed in the operating room, where LVOT pressure gradient after SM was measured with premature ventricular contraction provocation.

Gated 3D-CTA. The details of cardiac 3D-CT and VM have been described previously.17 In brief, a 320-detector low volumetric scanner (Aquilion One; Toshiba America Medical System) was used to perform a 350 msec continuous ECG-gated volume scan of the heart, focusing on the late diastolic phase (90% of the R-R interval). The resulting images were postprocessed with Vitrea software (Vital Images). 3D reconstruction was performed to visualize areas of LV hypertrophy and surrounding structures associated with relevant surgical anatomies. The volumes of total LV myocardium and septal band were calculated. In addition, the thickness in 17 segments of LV myocardium, including the ventricular septum were measured.

Surgical procedure. SM was recommended based on the contemporary HCM guidelines.14,15 We have introduced 2 concepts toward making SM more objective: septal band (Figure E1) and VM (Figure E2).12 Although not an accepted anatomical concept, the septal band is a characteristic hypertrophic continuous septal structure seen in HCM with basal LVOT obstruction, which starts basally beneath the left coronary annulus, running obliquely in a clockwise fashion along the septal wall down to the base of the posteromedial papillary muscle. Resecting this band ameliorates the obstruction. VM is a preoperative assessment tool to objectively measure the extent and volume of the myocardial resection using 3-dimensional computed tomography (3D-CT). Use of 3D-CT provided us with a unique opportunity to study LV remodeling following SM.

In the present study, we hypothesized that SM would lead to remodeling of the LV myocardium beyond the resection area, and evaluated the changes of the LV myocardial volume in detail following SM.

METHODS

Study Design and Patient Selection

This is a single-center retrospective study approved by Columbia University Medical Center Institutional Review Board. Obtaining informed consent was waived because of the retrospective nature of this study (IRB No.: AAAT2539, first approval date: August 11, 2020, and most recent approval date: November 16, 2020).

Fifty patients with obstructive HCM who underwent SM at our institution between March 2016 and July 2020 were retrospectively reviewed and analyzed. Preoperative demographic characteristics, CT and echocardiographic (ECG) data, procedure-related details, and postoperative complications (following the definition of the Society of Thoracic Surgery Adult Cardiac Database version 2.9 whenever available) were collected by reviewing electronic medical records. Recent 19 consecutive patients underwent postoperative ECG-gated cardiac CT angiogram (CTA) in addition to preoperative CTA. In these patients, volumes of the septal band and thickness of the 17 LV myocardial segments, as recommended by the American Heart Association Standardized Myocardial Segmentation and Nomenclature for tomographic imaging guidance,11 were measured to determine the changes following SM. Postoperative ECG-gated cardiac CTA was done at a median of 2.5 months (interquartile range [IQR], 1.8–3.4 months) after surgery. Specifically, 3 patients underwent postoperative CTA within 1 month, 11 patients between 1 and 3 months, 3 patients between 3 and 6 months, and 2 patients between 6 months and 1 year after surgery.

Abbreviations and Acronyms

| Abbreviation | Definition |
|--------------|------------|
| 3D-CT        | 3-dimensional computed tomography |
| AF           | Atrial fibrillation |
| CTA          | Computed tomography angiogram |
| ECG          | Electrocardiogram |
| HCM          | Hypertrophic cardiomyopathy |
| LV           | Left ventricle |
| LVOT         | Left ventricular outflow tract |
| NYHA         | New York Heart Association |
| SAM          | Systolic anterior motion |
| SM           | Septal myectomy |
| TEE          | Transesophageal echocardiography |
| TTE          | Transthoracic echocardiography |
| VM           | Virtual myectomy |

To view the AATS Annual Meeting Webcast, see the URL next to the webcast thumbnail.

However, it has been demonstrated that there is no direct relationship between symptoms of heart failure and the degree of LV hypertrophy,9 and little is known about how and which part of the LV myocardium is affected by the reduction in LVOT pressure gradient after septal reduction therapy. Considering that the magnitude of LV hypertrophy is associated with sudden cardiac death and an important predictor of outcome in patients with HCM,10,11 changes in LV myocardial mass may have an implication in the prognosis.

In an effort to make SM more reproducible, we have introduced 2 surgical concepts: septal band and virtual myectomy (VM).12 The septal band is a characteristic hypertrophic septal structure seen in HCM with basal LVOT obstruction, which extends from beneath the left coronary annulus, running obliquely in a clockwise fashion along the septal wall down to the base of the posteromedial papillary muscle. Resecting this band ameliorates the obstruction. VM is a preoperative assessment tool to objectively measure the extent and volume of the myocardial resection using 3-dimensional computed tomography (3D-CT). Use of 3D-CT provided us with a unique opportunity to study LV remodeling following SM.

In the present study, we hypothesized that SM would lead to remodeling of the LV myocardium beyond the resection area, and evaluated the changes of the LV myocardial volume in detail following SM.
During SM, the septal band was resected to achieve the VM-predicted resection volume.

Mitral valve intervention was added whenever deemed appropriate, typically for abnormal secondary chordae or papillary muscles inserting to the anterior mitral leaflet. Patients with preoperative atrial fibrillation (AF) underwent surgical ablation procedure with pulmonary vein isolation and left atrial appendage closure. Anatomical assessment of the LVOT and pressure measurement were performed before and after cardiopulmonary bypass under TEE guidance to confirm the appropriateness of SM.

Statistical Analysis

All statistical analyses were performed with R version 4.0.0 (R Foundation for Statistical Computing). Continuous variables were tested for normality using the Kolmogorov-Smirnov test. Nonnormality variables were expressed as median (IQR), whereas normally distributed variables were mean ± SD. Categorical data were described with numbers and percentages of the total. All statistical test values were 2-sided.

The Friedman test was used to compare echocardiography data at 4 time points, and the post hoc Bonferroni correction was applied to assess differences in variables in 6 pairwise comparisons using the Wilcoxon signed rank test. To declare statistical significance between these 4 time points, 6 different multiple comparisons must be made, so the P value must be less than .0083 (.05 divided by 6). The difference in incidence of septal anterior motion was analyzed using the Cochran Q test. A linear model was run to compare the pre- and postoperative data for CTA. These data were measured from the same patient at 2 different time points and are necessarily linked. Therefore, the paired t test was driven to compare the mean values between the corresponding patients. The Pearson product moment correlation coefficient was also used to obtain the r value and associated P value.

To evaluate the interobserver bias, VM was blindly performed by 2 physicians (Y.T. and K.A.), and the Bland-Altman plot was created to examine whether systematic errors were introduced into the measurements (Figure E3).

RESULTS

Patient Characteristics

The baseline characteristics of the patients are listed in Table 1. The median age was 58.0 years (IQR, 48.3-64.0 years) with 50% women. Diabetes was seen in 14% and AF in 24%. Syncopal episode occurred in 16% of patients. One patient presented with infective endocarditis involving both the aortic and mitral valves. Preoperative New York Heart Association (NYHA) functional class 3 or greater was observed in 56% of patients with the mean preoperative NYHA functional class of 2.5 ± 0.8. The echocardiographic results are summarized in Table 2. The LV end-diastolic diameter was 43.9 ± 5.4 mm with LV ejection fraction of 66.1% ± 4.9%. LVOT pressure gradient at rest was 74.0 mm Hg (IQR, 42.5-92.5 mm Hg), and ventricular septal thickness was 20.0 mm (IQR, 17.0-24.0 mm). Systolic anterior motion (SAM) was found in 86% of patients, and moderate or greater mitral regurgitation in 56%. The indications for myectomy in patients without SAM were midventricular type in 3 patients, HCM with severe LVOT obstruction complicated by infective endocarditis in 1 patient, and HCM with severe LVOT obstruction in 2 patients. None of the patients we analyzed had apical type.

Operative Details

Intraoperative data are described in Table 3. The mean myocardial resection volume predicted by VM was 6.7 ± 3.3 mL, and the actual resection volume was 6.4 ± 2.7 mL (r = 0.72; P < .001). Isolated SM was performed in 36% (18 out of 50) of patients. Mitral valve intervention was performed in 56% (28 out of 50) of patients, of whom 23 underwent mitral valvuloplasty and 5 underwent mitral valve replacement. Mitral valvuloplasty consisted of abnormal chord resection in 21 cases, papillary muscle realignment in 2 cases, and leaflet plication in 4 cases. Mitral valve replacement was performed for infective endocarditis (n = 1), extensive fibrosis of the valve leaflets (n = 1), bileaflet tethering due to chordae shortening (n = 1), and excessive thickening and foreshortening of the anterior leaflet (n = 2). The aortic valve procedure included 2 valve repairs for aortic insufficiency, and 2 valve replacements for aortic stenosis or infective endocarditis. All 12 patients with preoperative AF had the surgical ablation with pulmonary vein isolation and left atrial appendage ligation. The cardiopulmonary bypass and aortic cross-clamp times were 124.5 min (IQR, 110.0-146.3 min) and 89.0 min (79.0-105.0 min), respectively.

| TABLE 1. Patient characteristics |
|-------------------------------|
| **Variable** | **Septal myectomy (N = 50)** |
| Age (y) | 58.0 (48.3-64.0) |
| Female sex | 25 (50.3) |
| Body surface area (m²) | 2.0 (1.9-2.2) |
| Hypertension | 33 (66.0) |
| Dyslipidemia | 21 (42.0) |
| Diabetes | 7 (14.0) |
| Hb | 13.5 (11.9-14.3) |
| Htc | 40.0 (36.7-43.2) |
| CAD | 6 (12.0) |
| CVD | 1 (2.0) |
| COPD | 3 (6.0) |
| PAD | 1 (2.0) |
| CKD | 6 (12.0) |
| AF | 12 (24.0) |
| Infective endocarditis | 1 (2.0) |
| NYHA functional class | 6 (12.0) |
| 1 | 2 (4.0) |
| 2 | 17 (34.0) |
| 3 | 25 (50.0) |
| 4 | 6 (12.0) |

Values are presented as median (interquartile range) or as n (%). Hb, Hemoglobin; Htc, hematocrit; CAD, coronary artery disease; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; PAD, peripheral artery disease; CKD, chronic kidney disease; AF, atrial fibrillation; NYHA, New York Heart Association.
TEE performed in the operating room after SM showed that the septal thickness decreased to 14.0 mm (IQR, 13.0–15.0 mm) and the LVOT pressure gradient improved to 10.0 mm Hg (IQR, 8.0–12.0 mm Hg). Moderate mitral regurgitation and SAM remained in 6% (3 out of 50) of patients. No postoperative ventricular septal defect was observed.

### Temporal Changes in ECG Parameters

The postmyectomy septal thickness did not change over time. The LVOT pressure gradient mildly increased at discharge (22.5 mm Hg [IQR, 15.0–34.5 mm Hg]) from 10.0 mm Hg [IQR, 8.0–12.0 mm Hg] at intraoperative TEE), and then decreased again at follow-up (15.5 mm Hg [12.1–21.5 mm Hg]). One of 3 patients with postoperative moderate residual mitral regurgitation and SAM had an improvement in SAM, and the other 2 patients remained unchanged.

### Changes in the LV Myocardium

Postoperative cardiac 3D-CTA showed that the septal band volume decreased from 9.8 ± 4.3 mL preoperatively to 4.1 ± 1.5 mL postoperatively, corresponding to the resection volume (r = 0.82; P < .001). On the other hand, the volume of the total LV myocardium decreased from 261.1 ± 84.3 mL to 248.2 ± 75.5 mL, a difference of 12.9 mL, which is beyond the actual resection volume (Figure 1). The changes in the wall thicknesses in 17 segments of LV myocardium (measured at end-diastole) are demonstrated in Figure 2. The mean change was 1.1 mm

---

**TABLE 2. Temporal changes in echocardiography results**

| Variable                  | Preoperative (n = 50) | Intraoperative (n = 50) | Discharge (n = 50) | Follow-up (n = 50) | P value |
|---------------------------|----------------------|------------------------|--------------------|--------------------|---------|
| LVEF (%)                  | 66.1 ± 4.9           | –                      | 61.7 ± 6.4         | 61.1 ± 7.0         | <.001* |
| LVEDD (mm)                | 43.9 ± 5.4           | –                      | 44.7 ± 6.1         | 45.0 ± 5.9         | .478‡   |
| LVESD (mm)                | 25.2 ± 4.8           | –                      | 28.5 ± 5.9         | 28.8 ± 5.8         | .148‡   |
| Peak LVOT PG (mm Hg)      | 74.0 (42.5–92.5)     | 10.0 (8.0–12.0)        | 22.5 (15.0–34.5)   | 15.5 (12.1–21.5)   | <.001*‡ |
| Ventricular septal thickness (mm) | 20.0 (17.0–24.0) | 14.0 (13.0–15.0) | 14.0 (13.0–15.5) | 14.0 (11.5–16.0) | <.001*‡ |
| Mitral regurgitation      |                       |                        |                    |                    |         |
| None                      | 2 (4.0)              | 16 (32.0)              | 12 (24.0)          | 22 (44.0)          | <.001*‡ |
| Trace                     | 5 (10.0)             | 8 (16.0)               | 16 (32.0)          | 13 (26.0)          |         |
| Mild                      | 15 (30.0)            | 23 (46.0)              | 19 (38.0)          | 12 (24.0)          |         |
| Moderate                  | 15 (30.0)            | 3 (6.0)                | 3 (6.0)            | 3 (6.0)            |         |
| Severe                    | 13 (26.0)            | 0                      | 0                  | 0                  |         |
| SAM                       | 43 (86.0)            | 3 (6.0)                | 2 (4.0)            | 2 (4.0)            | <.001   |

Values are presented as mean ± SD, median (interquartile range), or n (%). LVEF, Left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; PG, pressure gradient; SAM, systolic anterior motion. *Significantly different between preoperative and discharge. †No difference in all the comparisons of the 4 groups. ‡Significantly different between preoperative and intraoperative. §Significantly different between intraoperative and discharge. ¶Significantly different between intraoperative and follow-up.

**TABLE 3. Operative details**

| Variable                  | Septal myectomy (N = 50) |
|---------------------------|--------------------------|
| Isolated septal myectomy  | 18 (36.0)                |
| Concomitant procedures    |                          |
| Aortic valve procedure    | 4 (8.0)                  |
| Mitral valve repair       | 23 (46.0)                |
| Abnormal chord resection  | 21 (42.0)                |
| Papillary muscle realignment | 2 (4.0)            |
| Leaflet plication         | 4 (8.0)                  |
| Mitral valve replacement  | 5 (10.0)                 |
| CABG                      | 1 (2.0)                  |
| Maze                      | 12 (24.0)                |
| LAA close                 | 21 (42.0)                |
| CPB time (min)            | 124.5 (110.0–146.3)      |
| ACC time (min)            | 89.0 (79.0–105.0)        |
| Predicted resection volume* (mL) | 6.7 ± 3.3        |
| Resection volume† (mL)    | 6.4 ± 2.7                |
| VSD                       | 0                        |

Values are presented as mean ± SD, median (interquartile range), or n (%). CABG, Coronary artery bypass graft; LAA, left atrial appendage; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; VSD, ventricular septal defect. *Virtual myectomy. †Virtual myectomy-guided septal myectomy.
The wall thickness significantly decreased in all segments except the basal inferior and basal inferolateral regions. In particular, a decrease >15% was observed in the regions mainly on the septal band, including the basal anteroseptal, basal inferoseptal, and mid-anteroseptal areas (Table 4).

DISCUSSION

In this study, we investigated the subsequent changes in the LV myocardium following SM. The main finding was that the LV myocardium after SM decreased more than the actual amount of resection, with significant reduces in almost all LV wall segments Figure 3.

3D-CTA allowed us to further study LV remodeling following SM. Most notably, the overall reduction in LV myocardial mass was significantly greater than the actual resection volume. The LV wall was divided into 17 sections to investigate the regional changes in myocardial thickness. The reduction in LV wall thickness was observed in all segments albeit with heterogeneous extents. Using ECG, Deb and colleagues17 measured LV mass and LV mass index preoperatively and postdischarge in patients who underwent SM for obstructive HCM, and reported that significant decreases in LV mass and LV mass index occurred early postoperatively. Similarly, Nguyen and colleagues18 described that LV mass index decreased during the early postoperative period after septal resection. A small case series with cardiac magnetic resonance imaging reported similar findings.19 Finally, Tang and colleagues20 showed that SM may lead to relative increase in the LV mass with late gadolinium enhancement; however, their data could be interpreted as unchanged fibrotic mass in the presence of regressed viable myocardial mass.21 Together, these data suggest significant contribution of afterload from LVOT obstruction to the LV hypertrophy in HCM. If this is the case, SM in the early stages of HCM, when there is still viable myocardium that can be remodeled before fibrosis progresses, is recommended. In fact, time from diagnosis to surgery has been identified as an independent factor in postoperative disease progression, including new onset of AF, NYHA functional class worsening, reintervention, and death, and the influence of taking more than 5 years to treat, even if successful in alleviating symptoms and LVOT gradients, is significant, with a 3.4-fold increase in risk of these diseases compared with treating <3 years.22

In addition to symptomatic improvement, SM has been reported to be associated with a number of clinical benefits: when SM relieves LV pressure loading, it also improves myocardial microcirculation and resolves ischemia.23 Furthermore, improvement in diastolic dysfunction combined with improvement in mitral regurgitation may resolve the pressure and volume load on the left atrium, and prevent new AF and secondary pulmonary hypertension, resulting in improved survival.24 On the other hand, despite successful SM, a number of patients die from cardiovascular causes in the long-term. In surgically untreated patients with HCM, a correlation has been identified between LV wall thickness and the risk of sudden death, progression to heart failure, and all-cause mortality.10 Given that the degree of LV hypertrophy is closely associated with the occurrence of fatal arrhythmias and sudden death, although it is possible that LV remodeling by SM itself may be directly related to improved survival, it has been reported that the degree of postoperative myocardial hypertrophy was not associated with these adverse events,10,25 and the mechanism remains to be elucidated.

|                          | Pre     | Post    | Change   | P value |
|--------------------------|---------|---------|----------|---------|
| Septal band (mL)         | 9.8 ± 4.3 | 4.1 ± 1.5 | −56.4%   | < .001  |
| Total LV mass (mL)       | 261.1 ± 84.3 | 248.2 ± 75.5 | −10.5%   | < .001  |
| LV wall thickness in 17  | 12.0 ± 4.0 | 10.9 ± 3.1 | −6.4%    | < .001  |

FIGURE 1. Left ventricle (LV) remodeling after septal myectomy: Assessment with 3-dimensional computed tomography (3D-CT) angiogram. The LV outflow tract obstruction has been removed and LV myocardium remodeling has occurred.
Further observation is needed to clarify the future course of these LV changes and their influence on a patient’s prognosis.

Limitations
This study was a single-center retrospective study with a small sample size, and thus the findings may not be generalizable. Furthermore, the timing of the postoperative CT was not consistent among patients. The small cohort size did not allow further adjustment upon analysis.

CONCLUSIONS
The present study showed that SM appears to induce remodeling of the entire LV myocardium, not just the resected area.

FIGURE 2. The 17 segments of left ventricle (LV) myocardium. Schematic representation of the 17 LV segments. Significant decreases in the LV myocardial mass in all segments except the basal inferior and basal inferolateral regions. Especially, decrease >15% was observed in the regions mainly on the septal band.

Further observation is needed to clarify the future course of these LV changes and their influence on a patient’s prognosis.
TABLE 4. Changes in segmental left ventricle (LV) wall thickness following virtual myectomy (VM)-guided septal myectomy (SM)

| LV segment       | Pre-SM (mm) (n = 19) | Post-SM (mm) (n = 19) | % Change (n = 19) | P value |
|------------------|----------------------|-----------------------|-------------------|---------|
| Basal            |                      |                       |                   |         |
| 1 Anterior       | 12.5 ± 5.4           | 11.5 ± 3.7            | −5.0              | .04     |
| 2 Anterosseptal  | 19.1 ± 3.6           | 16.6 ± 4.3            | −16.0             | <.001   |
| 3 Inferoseptal   | 13.5 ± 4.2           | 11.9 ± 5.0            | −15.0             | .003    |
| 4 Inferior       | 10.5 ± 1.8           | 10.3 ± 1.8            | −2.0              | .07     |
| 5 Inferolateral  | 10.3 ± 1.2           | 10.2 ± 1.4            | −1.0              | .219    |
| 6 Anterolateral  | 12.0 ± 2.6           | 11.5 ± 2.0            | −4.2              | .017    |
| Mid              |                      |                       |                   |         |
| 7 Anterior       | 11.2 ± 2.2           | 10.4 ± 2.1            | −7.2              | .002    |
| 8 Anterosseptal  | 17.3 ± 4.4           | 14.4 ± 2.9            | −16.5             | <.001   |
| 9 Inferoseptal   | 13.7 ± 4.4           | 12.6 ± 3.7            | −9.1              | .039    |
| 10 Inferior      | 10.6 ± 1.7           | 10.4 ± 1.8            | −3.5              | .004    |
| 11 Inferolateral | 10.3 ± 1.3           | 10.2 ± 1.5            | −3.0              | .03     |
| 12 Anterolateral | 11.0 ± 2.4           | 10.7 ± 2.2            | −3.9              | .009    |
| Apical           |                      |                       |                   |         |
| 13 Anterior      | 11.2 ± 3.5           | 10.6 ± 3.0            | −6.5              | .001    |
| 14 Septal        | 11.4 ± 3.4           | 10.9 ± 3.3            | −6.5              | .028    |
| 15 Inferior      | 9.8 ± 3.0            | 9.2 ± 2.4             | −6.4              | .005    |
| 16 Lateral       | 10.0 ± 2.8           | 9.4 ± 2.4             | −6.5              | .005    |
| Apex             |                      |                       |                   |         |
| 17 Apex          | 9.8 ± 3.0            | 9.2 ± 2.5             | −6.4              | .025    |

Webcast
You can watch a Webcast of this AATS meeting presentation by going to https://aats.blob.core.windows.net/media/Publications/AM21_A05%20-%20HOCM%20and%20LV%20Remodeling.mp4-PresPlusDisc.mp4.

Conflict of Interest Statement
The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

The authors thank Yanling Zhao for statistical advice and Atsushi Kainuma for data measurement.

References
1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
2. Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019;9(Suppl 2):S88-415.
3. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 1987;76(5 Pt 2):V104-8.
4. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg. 1995;110:193-206.
5. Spaziano M, Sawaya FJ, Lefèvre T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: indications, technical aspects, and clinical outcomes. J Invasive Cardiol. 2017;29:404-10.
6. Woo A, Williams WG, Choi R, Wigle ED, Rozenblum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in hypertrophic cardiomyopathy. Circulation. 2005;111:2033-41.
7. Smedra NG, Lytle BW, Lever HM, Rajaswaram J, Krishnaswamy G, Kaple RK, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127-33.
8. Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517-23.
9. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, et al. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol. 2005;95:1329-33.
10. Spiriito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-85.
11. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-4.
12. Takayama H, Yu SN, Sorabella R, Leb J, Pulerwitz TC, Cooper C, et al. Virtual septal myectomy for preoperative planning in hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2019;158:455-63.
13. Cerqueira MD, Weissman NJ, DiSanzio V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42.
14. Gersh BJ, Maron BJ, Benow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124:2761-96.
15. Elliott PM, Anastasakis A, Borger MA, Borggreve M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic
cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). **Eur Heart J.** 2014;35:2733-79.

16. Fukuhara S, Edwards S, Kurlansky P, Takayama H. Bimanual examination for septal myectomy for hypertrophic cardiomyopathy. *Interact Cardiovasc Thorac Surg.* 2014;19:735-7.

17. Deb SJ, Schaff HV, Dearani JA, Nishimura RA, Ommen SR. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. *Ann Thorac Surg.* 2004;78:2118-22.

18. Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Lahm BD, et al. Determinants of reverse remodeling of the left atrium after transaortic myectomy. *Ann Thorac Surg.* 2018;106:447-53.

19. El-Hamamsy I, Lekadir K, Olivotto I, El Guindy A, Merrifield R, Rega L, et al. Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. *Glob Cardiol Sci Pract.* 2012:2012:9.

20. Tang B, Song Y, Yang Q, Cui H, Ji K, Zhao S, et al. Changes in left atrial function, left ventricle remodeling, and fibrosis after septal myectomy for obstructive hypertrophic cardiomyopathy. *J Thorac Cardiovasc Surg.* 2022;163:1828-34.

21. Blitzer D, Weiner SD, Nguyen SN, Takayama H. Commentary: left heart remodeling with septal myectomy: fibrosis is a relative but not absolute concern. *J Thorac Cardiovasc Surg.* 2022;163:1837-8.

22. Cavigli L, Fumagalli C, Maurizi N, Rossi A, Arretime A, Targetti M, et al. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. *Int J Cardiol.* 2018;273:155-61.

23. Jorg-Cipor M, Namdar M, Turina J, Jenni R, Schwitter J, Turina M, et al. Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy. *J Thorac Cardiovasc Surg.* 2004;128:163-9.

24. Fenech D, Haddad F, Pavlovic A, Sinagra G, Schmittner I, Knowles JW, et al. Latent obstruction and left atrial size are predictors of clinical deterioration leading to septal reduction in hypertrophic cardiomyopathy. *J Card Fail.* 2014:20:236-43.

25. Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy. *J Thorac Cardiovasc Surg.* 2011;141:439-45.

Key Words: hypertrophic cardiomyopathy, left ventricular outflow tract obstruction, septal myectomy, left ventricular myocardium remodeling, 3-dimensional computed tomography, systolic anterior motion, mitral regurgitation

**Discussion**

Presenter: Dr Tsuyoshi Yamabe

**Dr Nicholas G. Smedira** *(Cleveland, Ohio).* I want to thank the Association for the opportunity to review this work and Dr Yamabe and Dr Takayama for a great presentation. It’s really well written. It’s very concise and to the point. I think there were 3 points they mentioned that are important and interesting. I think among the most important points for the readers and for those viewing this talk is their idea of a septal band. They had previously published this concept, but I had not seen that publication. I think it’s a really critical observation postulating that there is an apparent band of muscle originating from the left trigone and then spiraling in a counterclockwise direction toward the posteromedial papillary muscle. The recognition of this pattern is critical when performing a standard myectomy to avoid the known complications associated with a myectomy such as a ventricular septal defect and the need for pacemakers. So, I congratulate the authors on this insight. I think it’s a really important insight. I’m going to ask some questions related to that.

They tried to answer the question of whether a myectomy results in regression of septal muscle remote from the septum. It is a small series, only 19 patients. They showed on average about a 6% reduction in the volume of the muscle in remote segments. And, interestingly, almost all the regression occurred within 90 days. I thought for a bit that 90 days is really fast. And then I remembered what happens to me when I stop exercising. I regress probably to my baseline state in less than 90 days, so that might be how muscle remodels, and it does so very quickly. It’s been shown in other treatments, including septal ablation that there is rapid regression of remote muscle hypertrophy.

I have a couple of questions to make sure I understand their methodologies. I’ll let the presenter respond after his question—are the measurements of the muscle segment volumes by the computed tomography angiography done by a computer algorithm, or are they done manually? And if they’re done manually, how do we know that they’re reliable and accurate measurements?

**Dr Tsuyoshi Yamabe** *(New York, NY).* Thank you everyone. Thank you for your question, Dr Smedira. As you pointed out, the reliability and reproducibility of the measurement are very important for this method to be generalized. At present, the measurement of muscle segment volume was done by a person manually. To assess the interobserver variability, the measurements were performed by 2 blinded physicians. The Bland-Altman plot showed the interclass correlation coefficient was 0.96, indicating high reproducibility. However, it’s important to point out that these 2 physicians received special training for the measurement. They repeated it a couple of times to actually measure in front of one expert and have him teach them the tips. We believe that the reliability of these measures needs to be confirmed by conducting more measurements in more cases and comparing the results with clinical outcomes.

**Dr Smedira.** That’s great. Well, that enhances the validity of your observations. I mentioned the septal band spiraling. Is it your sense that this is a real anatomical structure inside the heart? Or is it just something that you’ve observed and it’s where the hypertrophy occurs? Is this a real structure?

**Dr Yamabe.** Yes. This is another excellent question. In the development of the virtual myectomy, our first few cases, we used a 3-dimensional printed model. It was after third or fourth case that we recognized the consistent
presence of the septal band and were surprised that this had not been previously described at autopsy. We did review multiple hearts in our pathology lab, and reached the conclusion that this structure cannot be seen postmortem because the heart is preserved in a contracted state, that is not at end diastole as is seen on computed tomography or when arrested in the operating room where the band is most obvious. Of course, its presence is difficult to appreciate in the operating room given the limited view through the aortic root. This structure is seen in all cases we have operated on with septal myectomy. Interestingly, it’s also seen on 3-dimensional computed tomography in afterload lesions such as aortic stenosis, although is a much less prominent structure.

Dr Smedira. Yes. I agree. Well, like anything else, once you’re aware of its existence, then you start to look for it. It is apparent more frequently than one would think. I know Dr Schaff has done a lot of apical myectomies. There’s so much variation in the morphology. Some patients don’t have basal hypertrophy rather it’s midventricular and apical. Do you think this band as it spirals can be hypertrophied in different segments?

Dr Yamabe. Yes, as you expect, majority of our patients had hypertrophic obstructive cardiomyopathy with typical anatomy with basal septal hypertrophy and systolic anterior motion. Based on our observation of several cases with combined basal and midventricular obstruction, we think the midventricular obstruction occurs when the septal band is prominent more toward the apex. On the other hand, apical hypertrophic cardiomyopathy may have a different mechanism, although in some cases, the band continues to the apex where it fuses with circumferential apical hypertrophy. We only had a few apical hypertrophic cardiomyopathy cases and don’t have enough data yet. What we do believe is the septal band likely represents hypertrophy of the most endocardial helical myofibers, and it forms an angle of roughly 45° with the centerline of the heart, essentially the same as the innermost layer of myocardium on pathological specimens. Further studies are needed to elucidate why this portion of the myocardium alone hypertrophies in hypertrophic cardiomyopathy.

Dr Smedira. Good. Thank you. This is a really important observation, and I want to thank you for that contribution.
FIGURE E1. The upper part of the figure is the base, where the left ventricular outflow tract and mitral valve annulus are located, and the lower part is the apex. Septal band is localized as a hypertrophic septal structure (darkest blue), which starts at the basal anterior wall and runs clockwise fashion when viewed from the apex, and generally continues to the mid inferior wall.

FIGURE E2. A, Longitudinal section of the left ventricle. Left ventricular myocardium is identified and segmented in a long axis image of computed tomography. B, Planned resection area in a 3-dimensional reconstruction image. The portion of septal band from the left trigone to the posteromedial papillary muscle (green) is the target resection area. The resection volume, extent, and thickness are rehearsed in the virtual myectomy. The membranous septum is indicated by a gray area. At present, the measurement of muscle segment volume was done by a person. To assess the interobserver variability, the measurements were performed by 2 blinded physicians who received a special training for the measurement and repeated a couple of times to actually measure in front of 1 expert and have him teach them the tips. The interclass correlation coefficient (2, 1) was 0.96 (95% CI, 0.93-0.98). Bland-Altman plots for the variability are shown in Figure E3. This graph suggested the presence of proportional error, where the difference in measurements increases in proportion to the amount of resection measured by virtual myectomy.
FIGURE E3. Bland-Altman plots of interobserver variability. The mean values of pairs of measurements are plotted against the difference between the measurements. The black continuous line represents the arithmetic mean and the black dotted lines represent 95% limits of agreement.